All In Biotech

Drug Trial Radar · NCT01949311

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials

Last checked: Nov 20, 2026Latest source record: Oct 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,733

Actual

Start

Oct 10, 2013

Primary completion

Jun 27, 2022

Study completion Jun 27, 2022

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Sep 24, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to assess the long-term safety of dupilumab administered in adult participants with atopic dermatitis (AD). The secondary objective of the study is to assess the immunogenicity of dupilumab in adult participants with AD, in the context of re-treatment, and to monitor efficacy parameters associated with long-term treatment. Optional Sub-Study: The primary objective of the sub-study is to assess the safety of the new dupilumab drug product in adult patients with AD after switching from the current dupilumab drug product. The secondary objectives of the sub-study are to evaluate systemic exposure and immunogenicity of the new dupilumab drug product in adult patients with AD.

Conditions

  • Atopic Dermatitis

Interventions

  • DupilumabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 272 weeks
  2. OPTIONAL SUB-STUDY: Number of Adverse Events of Special Interest (AESIs) Through the Last Study Visit After Switching to the New Dupilumab Drug ProductTime frame: Up to 24 Weeks

Locations

432 sites in 28 countries. Site status is shown where the registry gives one.

  • Regeneron Study Site

    Anniston, Alabama

  • Regeneron Study Site

    Birmingham, Alabama

  • Regeneron Study Site 1

    Birmingham, Alabama

  • Regeneron Study Site 2

    Birmingham, Alabama

  • Regeneron Study Site 2

    Phoenix, Arizona

  • Regeneron Study Site 3

    Phoenix, Arizona

  • Regeneron Study Site 1

    Phoenix, Arizona

  • Regeneron Study Site

    Fort Smith, Arkansas

  • Regeneron Study Site

    Rogers, Arkansas

  • Regeneron Study Site

    Bakersfield, California

  • Regeneron Study Site

    Clovis, California

  • Regeneron Study Site

    Costa Mesa, California

  • Regeneron Study Site

    Encinitas, California

  • Regeneron Study Site

    Fremont, California

  • Regeneron Study Site

    Lomita, California

  • Regeneron Study Site

    Long Beach, California

  • Regeneron Study Site 1

    Los Angeles, California

  • Regeneron Study Site 2

    Los Angeles, California

  • Regeneron Study Site

    Los Angeles, California

  • Regeneron Study Site

    Oceanside, California

  • Regeneron Study Site

    Orange, California

  • Regeneron Study Site

    Rolling Hills Estates, California

  • Regeneron Study Site

    San Diego, California

  • Regeneron Study Site 1

    San Diego, California

  • Regeneron Study Site 2

    San Diego, California

  • Regeneron Study Site

    Santa Monica, California

  • Regeneron Study Site

    Centennial, Colorado

  • Regeneron Study Site

    Denver, Colorado

  • Regeneron Study Site

    Denver, Colorado

  • Regeneron Study Site

    Trumbull, Connecticut

  • Regeneron Study Site

    Washington D.C., District of Columbia

  • Regeneron Study Site

    Boca Raton, Florida

  • Regeneron Study Site

    Clearwater, Florida

  • Regeneron Study Site

    Fort Lauderdale, Florida

  • Regeneron Study Site 1

    Jacksonville, Florida

  • Regeneron Study Site 2

    Jacksonville, Florida

  • Regeneron Study Site

    Lake Worth, Florida

  • Regeneron Study Site

    Miami, Florida

  • Regeneron Study Site

    Miami, Florida

  • Regeneron Study Site

    Miami Lakes, Florida

Showing 40 of 432 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.